Results 91 to 100 of about 61,737 (200)

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis

Diseases
Background: There is still debate whether ribavirin should be added to direct-acting antivirals (DAAs) for the management of treatment-experienced individuals with non-genotype-1 hepatitis C.
Shahd Hamran, Amani A. Al-Rajhi, Kawthar Jasim, Majed A. Al-Theyab, Mohamed Elahtam, Mooza K. Al-Hail, Wadha Al-Fahaidi, Yaman A. Khamis, Yara Dweidri, Abdel-Naser Elzouki, Tawanda Chivese   +10 more
doaj   +1 more source

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis

Clinical and Experimental Gastroenterology, 2012
Eric Druyts1, Edward J Mills1,2, Jean Nachega3, Christopher O'Regan4, Curtis L Cooper51Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada; 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON,
O'Regan C, Nachega J, Mills EJ, Druyts E, Cooper CL   +4 more
doaj  

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.

Gastroenterology, 2017
P. Kwo, E. Gane, C. Peng, Brian L. Pearlman, J. Vierling, L. Serfaty, M. Buti, S. Shafran, P. Stryszak, Li Lin, J. Gress, Stuart Black, F. Dutko, M. Robertson, J. Wahl, Lisa C Lupinacci, E. Barr, B. Haber   +17 more
semanticscholar   +1 more source

Ribavirin

Infectious Diseases Newsletter, 1985
openaire   +2 more sources

Short-Term Clinical and Immunologic Outcomes Conditional on SVR12 in Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Treated With Direct-Acting Antivirals: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Boonpheng B, Ungprasert P.
europepmc   +1 more source

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Lancet. Infectious Diseases (Print), 2016
M. Manns, D. Samuel, E. Gane, D. Mutimer, G. McCaughan, M. Buti, M. Prieto, J. Calleja, M. Peck‐Radosavljevic, B. Müllhaupt, K. Agarwal, P. Angus, E. Yoshida, M. Colombo, M. Rizzetto, H. Dvory‐Sobol, J. Denning, S. Arterburn, P. Pang, D. Brainard, J. Mchutchison, J. Dufour, H. Van Vlierberghe, B. van Hoek, X. Forns   +24 more
semanticscholar   +1 more source

Crimean-Congo haemorrhagic fever in pregnancy: clinical outcomes and public health implications. [PDF]

Front Public Health
Kahraman E, Celina SS.
europepmc   +1 more source

Ribavirin pharmacokinetics

The Pediatric Infectious Disease Journal, 1990
openaire   +3 more sources

Reactive oxygen species promotion drives auranofin's antiviral activity against hepatitis E virus. [PDF]

J Virol
Tiller K, Williams ST, Wang B, Tian D, Meng X-J, Weger-Lucarelli J.   +5 more
europepmc   +1 more source

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

New England Journal of Medicine, 2004
F. Torriani, M. Rodríguez-Torres, J. Rockstroh, E. Lissen, J. González-García, A. Lazzarin, G. Carosi, J. Sasadeusz, C. Katlama, J. Montaner, H. Sette, S. Passe, J. De Pamphilis, F. Duff, U. M. Schrenk, D. Dieterich   +15 more
semanticscholar   +1 more source